Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials | Zendy

Ann Lin | Zendy; Christopher J. Giuliano | Zendy; Ann Palladino | Zendy; Kristen M. John | Zendy; Connor Abramowicz | Zendy; Monet Lou Yuan | Zendy; Erin L. Sausville | Zendy; Devon A. Lukow | Zendy; Luwei Liu | Zendy; Alexander R. Chait | Zendy; Zachary Galluzzo | Zendy; Clara Tucker | Zendy; Jason M. Sheltzer | Zendy

AI Assistant Blog Pricing

Open Access

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Author(s) -

Ann Lin,

Christopher J. Giuliano,

Ann Palladino,

Kristen M. John,

Connor Abramowicz,

Monet Lou Yuan,

Erin L. Sausville,

Devon A. Lukow,

Luwei Liu,

Alexander R. Chait,

Zachary Galluzzo,

Clara Tucker,

Jason M. Sheltzer

Publication year - 2019

Publication title -

science translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.819

H-Index - 216

eISSN - 1946-6242

pISSN - 1946-6234

DOI - 10.1126/scitranslmed.aaw8412

Subject(s) - clinical trial , toxicity , drug , biology , cancer drugs , drug toxicity , mechanism of action , pharmacology , cancer , cancer cell , mechanism (biology) , crispr , bioinformatics , cancer research , medicine , computational biology , in vitro , genetics , gene , philosophy , epistemology

CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog